All News

4 August 2012

U.S. FDA Approves ZALTRAP (ziv-aflibercept) After Priority Review for Previously Treated Metastatic Colorectal CancerAntibodies

2 August 2012

Baxter Confirms Receipt of Complete Response Letter on HyQAntibodies

31 July 2012

Regeneron Receives Complete Response Letter From FDA for ARCALYST (rilonacept) sBLA for the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering TherapiesAntibodies

31 July 2012

Mersana Therapeutics Raises $27M to Advance Fleximer Antibody-drug ConjugatesAntibodies

30 July 2012

New Published Paper Shows Efficacy of Lpath’s Anti-LPA Antibody, Lpathomab, in Spinal Cord Injury ModelsAntibodies

28 July 2012

SuppreMol begins development of Anti-IL-3 monoclonal antibody to diagnose and treat early stage Rheumatoid ArthritisAntibodies

27 July 2012

Genentech Reports Second Positive Study of ACTEMRA Given by Subcutaneous Injection to Patients with Rheumatoid ArthritisAntibodies

26 July 2012

FDA Advisory Committee Unanimously Recommends Approval of Lucentis for Treatment of Diabetic Macular Edema (DME)Antibodies

26 July 2012

Apogenix GmbH: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial in Treatment of Recurrent GlioblastomaAntibodies

24 July 2012

Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab Phase 3 ProgramAntibodies

22 July 2012

Millennium and Takeda Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS (brentuximab vedotin) in EuropeAntibodies

20 July 2012

Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 AntibodyAntibodies

17 July 2012

Biotest AG starts combination therapy study with BT-062 in multiple myelomaAntibodies

17 July 2012

Janssen Submits Applications Requesting Approval of Simponi In U.S. And Europe for Treatment of Moderately to Severely Active Ulcerative ColitisAntibodies

16 July 2012

Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 PopulationAntibodies

13 July 2012

OncoMed Pharmaceuticals Initiates Phase I Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-54F28 (Fzd8-Fc)Antibodies

11 July 2012

Research Corporation Technologies Demonstrates Long Half-Life of the CH2 Domain, a New Antibody-Derived ScaffoldAntibodies

11 July 2012

BioInvent International: Announcement of Topline Results from the GLACIER StudyAntibodies

11 July 2012

ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors Over-Expressing Its Folate Receptor TargetAntibodies

10 July 2012

Human Genome Sciences Announces Resubmission of Raxibacumab BLA to FDAAntibodies

8 July 2012

FDA Approves ERBITUX(R) (cetuximab) as First-Line Treatment in KRAS Mutation-Negative (Wild-Type) Epidermal Growth Factor Receptor (EGFR)-Expressing Metastatic Colorectal Cancer in Combination with FOLFIRI (Irinotecan, 5-Fluorouracil, Leucovorin)Antibodies

6 July 2012

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug ConjugatesAntibodies

5 July 2012

Merck: EXPAND Trial of Erbitux in Advanced Gastric Cancer Does Not Meet Primary EndpointAntibodies

4 July 2012

PNAS Publishes OncoMed Data Demonstrating Potent Anti-Cancer Activity for Novel Wnt Pathway Antibody OMP-18R5Antibodies

28 June 2012

Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of BlisibimodAntibodies

27 June 2012

XOMA Initiates Phase 3 Gevokizumab Trial in Patients With Non-Infectious Uveitis and Phase 2 Gevokizumab Trial in Patients With Erosive OsteoarthritisAntibodies

25 June 2012

Baxter Announces FDA Approval for GAMMAGARD LIQUID as a Treatment for Multifocal Motor NeuropathyAntibodies

25 June 2012

KaloBios’ KB001 Demonstrates Safety, Potential as New Approach to Preventing Pseudomonas Ventilator Associated PneumoniaAntibodies

22 June 2012

AbGenomics International Inc. has Raised $11 Million For Advancing its Therapeutic Antibodies for Autoimmune Diseases and CancersAntibodies

22 June 2012

New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech’s PerjetaAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Adalimumab (Humira) Biosimilars Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Report Package: Bispecific Antibodies

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing